Contra-indicated in patients with a history of clinically significant cardiovascular disease, congestive heart failure, cardiac hypertrophy, arrhythmia, or bradycardia.
Not available in the USA.
- TRADE NAME: Serdolect (Lundbeck)
- INDICATIONS: Schizophrenia
- CLASS: Antipsychotic
- HALF-LIFE: 2–4 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antiarrhythmics, Antidepressants, Antihistamines, Astemizole, Cimetidine, CYP3A inhibitors, Macrolides, Quinidine, Quinolones, Sotalol, Terfenadine
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sertindole in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/11/2023
